A Chinese biotechnology company has claimed that a new anti-aging pill could potentially extend human life up to 150 years. However, scientists stress that the claim is not yet proven in humans.
The company, Shenzhen-based Lonvi Biosciences, is developing a capsule built around Procyanidin C1, also known as PCC1. This compound is derived from grape seed extract.
What the Anti-Aging Compound Targets
The proposed pill focuses on senescent cells. These are often called “zombie cells” because they stop dividing but remain active in the body.
Over time, these cells may contribute to inflammation and age-related diseases. Therefore, researchers believe targeting them could improve health in later life.
Lonvi Biosciences claims PCC1 may help reduce the impact of these cells. As a result, the company suggests it could support longer and healthier lifespans.
Scientific Evidence Still Limited
Despite bold claims, current evidence remains limited to early research. The most cited study on PCC1 was published in 2021 in Nature Metabolism.
That study showed improved health and longer lifespan in mice. It also suggested positive effects on senescent cells in animal models.
However, researchers emphasize a key limitation. Results in mice do not always apply to humans. Therefore, human trials are essential before any confirmation.
Scientists continue to call for controlled clinical studies. These studies must test safety, effectiveness, and real-life impact on human aging.
Experts Urge Caution Over Longevity Claims
Experts have warned against accepting lifespan claims without strong clinical evidence. They state that current data does not confirm human life extension.
Although PCC1 appears promising in early research, it remains experimental. There is no verified proof that it can extend human life significantly.
Researchers also highlight the complexity of aging. They note that aging involves multiple biological systems, not a single pathway.
Growing Global Interest in Anti-Aging Research
The claim reflects increasing global interest in longevity science. Many biotechnology companies are now exploring treatments that target aging itself.
Instead of focusing only on diseases, researchers aim to slow biological aging processes. This approach is gaining attention in medical science.
China, in particular, is investing heavily in biotechnology innovation. Longevity research has become a key area of scientific development.
Conclusion: Promising Science, But No Proof Yet
The idea of a pill extending human life to 150 years remains unproven. While early studies show interesting results, human evidence is still missing.
For now, the Lonvi Biosciences pill remains an experimental concept. Its future depends on further clinical trials and scientific validation.
